newsfilter
← Latest News
GlobeNewswire·

Jounce Therapeutics Progresses INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and Pimivalimab (PD-1 Inhibitor) Combination Therapy in Patients with Advanced Solid Tumors

- Enrollment initiated in tumor-specific monotherapy and pimivalimab combination expansion cohorts – - Monotherapy and pimivalimab combination dose escalation enrollment completed - CAMBRIDGE, Mass., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Jounce Th